N4P N4 Pharma Plc

TIDMN4P

RNS Number : 0451P

N4 Pharma PLC

23 May 2018

N4 Pharma Plc

Result of meeting

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company which improves the delivery of existing drugs and novel vaccines and therapeutics, announces that at its Annual General Meeting held earlier today, all resolutions were duly passed.

Enquiries:

 
 N4 Pharma               Via Alma PR 
  CEO, Nigel Theobald 
 Stockdale Securities    Tel: +44(0)207 601 
  Tom Griffiths           6100 
 Alma PR                 Tel: +44(0)778 090 
  Josh Royston            1979 
  Robyn Fisher            Tel: +44(0)754 070 
                          6191 
 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance.

N4 Pharma's reformulation work falls under two divisions:

-- generic, already commercialised, drugs; and

-- delivery of novel and existing vaccines and therapeutics.

N4 Pharma has identified a number of established drugs that could be improved upon through its reformulation techniques. N4 Pharma's most advanced reformulation is for sildenafil, widely marketed as Viagra(TM), where N4 Pharma is seeking to improve the speed at which the drug takes effect whilst also extending its duration of action.

N4 Pharma's reformulation approach should take approximately three years to obtain regulatory approval as opposed to the traditional process for new drugs of on average ten years. The cost and risk profile of this model is also significantly less than the traditional process. N4 Pharma's business model for generics is to take reformulated drugs from its portfolio through to the stage where it will license its newly reformulated drugs to pharmaceutical companies to commercialise them. N4 Pharma's revenues should be derived from up front milestone and royalty payments associated with the licence.

N4 Pharma's business model for vaccines is to undertake the required clinical work to demonstrate the capability of its delivery system as a cancer vaccine or therapeutic treatment so that it can license the technology to major players developing treatments in this area, again in return for up front milestone and royalty payments associated with the licence.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

RAGBGGDUGXDBGIX

(END) Dow Jones Newswires

May 23, 2018 06:31 ET (10:31 GMT)

N4 Pharma (LSE:N4P)
Historical Stock Chart
From Apr 2024 to May 2024

N4 Pharma (LSE:N4P)
Historical Stock Chart
From May 2023 to May 2024